Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease

被引:20
|
作者
Heilman, Kenneth M. [1 ,3 ,4 ,5 ]
Nadeau, Stephen E. [2 ,3 ,4 ,5 ]
机构
[1] Malcom Randall VA Med Ctr, Geriatr Res Educ & Clin Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[2] Malcom Randall VA Med Ctr, Res Serv, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[3] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[4] Univ Florida, Coll Med, Malcom Randall VA Med Ctr, Gainesville, FL 32611 USA
[5] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA
关键词
Alzheimer's disease; Emotional facial expression; Emotional prosody; Alexithymia; Agitation; aggression; Depression; Psychosis; Sleep disorders; ATYPICAL ANTIPSYCHOTIC MEDICATIONS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PSYCHOLOGICAL SYMPTOMS; BEHAVIORAL DISTURBANCES; OLDER-ADULTS; NONPHARMACOLOGICAL INTERVENTIONS; CHOLINESTERASE-INHIBITORS; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA;
D O I
10.1007/s13311-021-01172-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease is associated with impairments in emotional communication including comprehension and production of facial emotional expressions, comprehension of affective prosody, and alexithymia. It is also associated with disorders of emotional experience including mood disorders (depression and anxiety), agitation/aggression, and psychosis. Agitation/aggression and psychosis are particularly disruptive, are associated with earlier institutionalization, and pose a major challenge to institutional management. Treatment of disorders of emotional experience has been primarily pharmacologic (reviewed here in detail) and has relied heavily on antipsychotic medications despite the small effect sizes demonstrated in a large number of randomized controlled trials and the prevalence of serious side effects associated with these drugs. Recent studies suggest that treatment with pimavanserin, an antipsychotic without activity at dopamine receptors, may represent an important advance for treatment of psychotic manifestations, even as the drug appears to pose significant risk. Dextromethorphan/quinidine may represent an important advance in the treatment of agitation/aggression. There is also compelling evidence that sleep disorders, which are common among patients with Alzheimer's disease and are readily treatable, may potentiate psychotic manifestations and agitation/aggression, but further studies are needed.
引用
收藏
页码:99 / 116
页数:18
相关论文
共 50 条
  • [1] Emotional and Neuropsychiatric Disorders Associated with Alzheimer’s Disease
    Kenneth M. Heilman
    Stephen E. Nadeau
    Neurotherapeutics, 2022, 19 : 99 - 116
  • [2] Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer's Disease
    Chen, Jiming
    Zhu, Zhengyao
    Xu, Fu
    Dou, Baomin
    Sheng, Zhutao
    Xu, Ying
    CELLS, 2025, 14 (03)
  • [3] Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease
    Cortes, Nicole
    Andrade, Victor
    Maccioni, Ricardo B.
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (03) : 899 - 910
  • [4] Causal influences of neuropsychiatric disorders on Alzheimer’s disease
    Ancha Baranova
    Qian Zhao
    Hongbao Cao
    Vikas Chandhoke
    Fuquan Zhang
    Translational Psychiatry, 14
  • [5] Causal influences of neuropsychiatric disorders on Alzheimer's disease
    Baranova, Ancha
    Zhao, Qian
    Cao, Hongbao
    Chandhoke, Vikas
    Zhang, Fuquan
    TRANSLATIONAL PSYCHIATRY, 2024, 14 (01)
  • [6] Big Data Analysis of Genes Associated With Neuropsychiatric Disorders in an Alzheimer's Disease Animal Model
    Ham, Suji
    Kim, Tae K.
    Hong, Heeok
    Kim, Yong S.
    Tang, Ya-Ping
    Im, Heh-In
    FRONTIERS IN NEUROSCIENCE, 2018, 12
  • [7] Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease
    Rusted, JM
    Newhouse, PA
    Levin, ED
    BEHAVIOURAL BRAIN RESEARCH, 2000, 113 (1-2) : 121 - 129
  • [8] Impact of Alzheimer's Disease and Related Disorders Neuropathology on Neuropsychiatric Symptoms
    Devanand, Davangere
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 57 - 57
  • [9] The glutamate synapse in neuropsychiatric disorders - Focus on schizophrenia and Alzheimer's disease
    Farber, NB
    Newcomer, JW
    Olney, JW
    GLUTAMATE SYNAPSE AS A THERAPEUTICAL TARGET: MOLECULAR ORGANIZATION AND PATHOLOGY OF THE GLUTAMATE SYNAPSE, 1998, 116 : 421 - 437
  • [10] Neuropsychiatric Symptoms Associated with Nutritional Status in Alzheimer's Disease
    Sherman, Chelsea
    Ruthirakuhan, Myuri
    Abraham, Eleenor
    Herrmann, Nathan
    Lanctot, Krista
    ANNALS OF NEUROLOGY, 2017, 82 : S152 - S152